NTI
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate
Created: | 2011-12-26 |
Last modified: | 2012-08-24 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 30 |
Chiral Atom Count | 0 |
Bond Count | 31 |
Aromatic Bond Count | 11 |
Chemical Component Summary | |
---|---|
Name | 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate |
Systematic Name (OpenEye OEToolkits) | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] ethanoate |
Formula | C12 H9 N3 O5 S |
Molecular Weight | 307.282 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2OC(=O)C |
SMILES | CACTVS | 3.370 | CC(=O)Oc1ccccc1C(=O)Nc2sc(cn2)[N+]([O-])=O |
SMILES | OpenEye OEToolkits | 1.7.6 | CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+](=O)[O-] |
Canonical SMILES | CACTVS | 3.370 | CC(=O)Oc1ccccc1C(=O)Nc2sc(cn2)[N+]([O-])=O |
Canonical SMILES | OpenEye OEToolkits | 1.7.6 | CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+](=O)[O-] |
InChI | InChI | 1.03 | InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17) |
InChIKey | InChI | 1.03 | YQNQNVDNTFHQSW-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank ID | DB00507 |
---|---|
Name | Nitazoxanide |
Groups |
|
Description | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths [A31976]. Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses [A31977]. |
Synonyms |
|
Brand Names |
|
Indication | For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>, and for the treatment of diarrhea in children caused by the protozoan, <i>Cryptosporidium parvum</i> [FDA label]. Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. |
Categories |
|
ATC-Code | P01AX11 |
CAS number | 55981-09-4 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Pyruvate synthase | MGKKMMTTDGNTATAHVAYAMSEVAAIYPITPSSTMGEEADDWAAQGRKN... | unknown | antagonist,inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 41684 |
ChEMBL | CHEMBL1401 |
ChEBI | CHEBI:94807 |
CCDC/CSD | QUZWOY, MABMOU, MABMUA, SOCMAA, SOCMEE, SOCMII |